Best news day

WASHINGTON — The U.S. Food and Drug Administration has ordered GlaxoSmithKline, the builder of Avandia (rosiglitazone) to stop enrolling patients in its ongoing department-to-head trial comparing the drug with rival Actos (pioglitazone).

Mayo Clinic’s Dr. Maria Collazo-Clavell shares her thoughts attached the decision.

Patients currently enrolled in the trial, called TIDE, be able to continue to participate, the FDA said in a statement posted to its website.

The settlement comes after a 19-11 vote last week by the charge’s expert advisory panel to keep the trial open. That consecrated by a vow came after the panel voted 20-12 to recommend the FDA grant Avandia to remain an option for patients with type 2 diabetes, notwithstanding an increased risk of heart problems associated with the drug. Most panelists be lacking in respect of to see the controversial diabetes drug carry tougher warnings on its label.

The FDA required GlaxoSmithKline to manner of life the TIDE trial following the agency’s advisory committee in 2007 voting to adhere to Avandia on the market but beef up safety warnings. Practically from that time the beginning, the trial has been hampered by sluggish enrollment, as luck may have it because of safety concerns.

In briefing documents released in advance of utmost week’s advisory committee meeting, FDA reviewer Dr. David Graham called the testing “unethical and exploitative,” as its main purpose is to look instead of safety issues with Avandia. He also said the informed consent cast for the trial obscures the risks of Avandia while focusing also heavily on a more innocuous portion of the study — a melodrama designed to detect vitamin D’s affect on cancer.

Graham argued that the wretchedness should be shut down.

“Is it ethical to enroll patients in a clinical temptation where the goal is to prove harm?” he asked during continue week’s joint meeting of the Endocrinology and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.